

# FPGEE for National Association of Boards of Pharmacy (NABP) Practice Exam (Sample)

## Study Guide



**Everything you need from our exam experts!**

**Copyright © 2025 by Examzify - A Kaluba Technologies Inc. product.**

**ALL RIGHTS RESERVED.**

**No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.**

**Notice: Examzify makes every reasonable effort to obtain from reliable sources accurate, complete, and timely information about this product.**

**SAMPLE**

## **Questions**

SAMPLE

- 1. What does a SWOT analysis help to identify?**
  - A. Profit and loss**
  - B. Market share**
  - C. Strengths, weaknesses, opportunities, threats**
  - D. Operational compliance**
- 2. What is the focus of pharmacodynamics?**
  - A. The study of how drugs are absorbed in the body**
  - B. The effects of drugs on biological systems**
  - C. The chemical composition of drugs**
  - D. The safety and toxicity of drugs**
- 3. What disease is marked by the softening of bone due to calcium and vitamin D deficiency?**
  - A. Osteoporosis**
  - B. Osteomalacia**
  - C. Fibromyalgia**
  - D. Rickets**
- 4. What is the main role of suspending agents in formulations?**
  - A. Increase viscosity and inhibit agglomeration**
  - B. Accelerate the rate of dissolution**
  - C. Provide flavoring to the product**
  - D. Enhance color and appearance**
- 5. Which of the following types of emulsions is formed using nonionic surfactants with a high HLB value?**
  - A. w/o emulsions**
  - B. o/w emulsions**
  - C. coarse emulsions**
  - D. aqueous emulsions**

- 6. What type of epithelium lines the alveoli of the lungs?**
- A. Cuboidal epithelium**
  - B. Squamous epithelium**
  - C. Columnar epithelium**
  - D. Transitional epithelium**
- 7. What is the acceptable droplet diameter range for an emulsion to be classified as coarse dispersion?**
- A. 1 nm to 0.1  $\mu\text{m}$**
  - B. 0.1  $\mu\text{m}$  to 10  $\mu\text{m}$**
  - C. 10  $\mu\text{m}$  to 100  $\mu\text{m}$**
  - D. 100  $\mu\text{m}$  and above**
- 8. Which form of DUR is performed after therapy has been completed?**
- A. Prospective DUR**
  - B. Concurrent DUR**
  - C. Retrospective DUR**
  - D. Preventive DUR**
- 9. Which agency is involved in coordinating and funding substance abuse and mental health programs?**
- A. FDA**
  - B. CMS**
  - C. SAMHSA**
  - D. NIH**
- 10. What defines low-risk level preparations according to USP 797?**
- A. Using nonsterile ingredients**
  - B. Multiple sterile product combinations**
  - C. Aseptic manipulations in ISO Class 5 conditions**
  - D. Long duration manipulations**

## **Answers**

SAMPLE

1. C
2. B
3. B
4. A
5. B
6. B
7. B
8. C
9. C
10. C

SAMPLE

## **Explanations**

SAMPLE



## 1. What does a SWOT analysis help to identify?

- A. Profit and loss
- B. Market share
- C. Strengths, weaknesses, opportunities, threats**
- D. Operational compliance

A SWOT analysis is a strategic planning tool that helps organizations identify their internal strengths and weaknesses, as well as external opportunities and threats. This four-part assessment allows companies to critically evaluate their current position and strategize accordingly. The strengths aspect focuses on resources and capabilities that give an organization an advantage, while weaknesses highlight areas that need improvement or pose challenges. Opportunities examine external conditions that could be advantageous for growth or improvement, and threats identify external challenges that could adversely affect the organization. This comprehensive view aids businesses in developing strategies that leverage their strengths to capitalize on opportunities while addressing weaknesses and mitigating threats. In contrast to the other options, which focus on specific metrics or compliance aspects, a SWOT analysis provides a broader framework for understanding both the internal and external factors that can influence an organization's success.

## 2. What is the focus of pharmacodynamics?

- A. The study of how drugs are absorbed in the body
- B. The effects of drugs on biological systems**
- C. The chemical composition of drugs
- D. The safety and toxicity of drugs

The focus of pharmacodynamics is on the effects of drugs on biological systems. This branch of pharmacology specifically investigates how drugs influence physiological functions, the mechanisms of action of drugs at various receptors or targets in the body, and the relationship between drug concentration and effect. It essentially analyzes the fundamental pharmacological effects of medications, including therapeutic effects and potential side effects, to understand how and why certain drugs can produce specific outcomes in patients. While the other options mention important aspects of pharmacology, they do not align with the core definition of pharmacodynamics. The study of absorption pertains to pharmacokinetics, which deals with how the body handles drugs over time. Chemical composition corresponds to the field of medicinal chemistry, focused on the design and development of new drugs. Safety and toxicity are critical considerations in drug development and usage but are primarily covered under pharmacovigilance and toxicology, not pharmacodynamics itself. Thus, the correct answer emphasizes the primary concern of pharmacodynamics: the effect of drugs on biological systems.

**3. What disease is marked by the softening of bone due to calcium and vitamin D deficiency?**

- A. Osteoporosis**
- B. Osteomalacia**
- C. Fibromyalgia**
- D. Rickets**

The condition characterized by the softening of bone due to deficiencies in calcium and vitamin D is osteomalacia. This disorder leads to a decrease in bone mineralization, resulting in bones that are unstable and prone to fractures. Osteomalacia primarily occurs in adults, whereas rickets is the equivalent condition seen in children. Vitamin D is vital for calcium absorption in the intestines, and a deficiency can lead to insufficient calcium levels in the body. This deficiency results in inadequate mineral content in bones, causing them to soften. Symptoms may include bone pain, muscle weakness, and an increased risk of fractures, which distinguishes it from other bone diseases like osteoporosis, where bone density decreases but the bones themselves are not soft. Considering the other options, osteoporosis is a condition where bones become brittle and fragile due to loss of density, typically seen in aging populations, but it does not involve softening of the bones directly related to nutritional deficiencies. Fibromyalgia is a syndrome characterized by widespread musculoskeletal pain and does not directly relate to bone health. Rickets is linked to similar deficiencies but occurs in developing skeletons of children, rather than in adults. Therefore, osteomalacia is the term specifically used for softening of the bones due to vitamin D and calcium deficiencies in adults

**4. What is the main role of suspending agents in formulations?**

- A. Increase viscosity and inhibit agglomeration**
- B. Accelerate the rate of dissolution**
- C. Provide flavoring to the product**
- D. Enhance color and appearance**

Suspending agents play a critical role in pharmaceutical formulations primarily by increasing viscosity and inhibiting agglomeration. The increased viscosity helps to maintain a uniform distribution of solid particles throughout a liquid formulation, ensuring that the active ingredients do not settle at the bottom over time. This is particularly important for suspensions, where the solid particles must remain evenly dispersed to deliver the intended dose effectively. Inhibiting agglomeration further supports this by preventing the solid particles from clumping together, which can lead to inconsistencies in dosing and effectiveness. By ensuring that the particles remain suspended, these agents contribute to the stability and efficacy of the medication, making them essential in formulations where active ingredients need to be evenly distributed for proper therapeutic effect. The other options relate to various characteristics of a formulation but do not accurately capture the primary function of suspending agents. While increasing viscosity and improving stability are crucial for maintaining the quality of the formulation, flavoring and color enhancement pertain more to the sensory attributes of a product rather than its functional stability.

**5. Which of the following types of emulsions is formed using nonionic surfactants with a high HLB value?**

**A. w/o emulsions**

**B. o/w emulsions**

**C. coarse emulsions**

**D. aqueous emulsions**

Nonionic surfactants with a high HLB (Hydrophilic-Lipophilic Balance) value are typically used to form oil-in-water (o/w) emulsions. The HLB scale ranges from 0 to 20, with lower values indicating a tendency to stabilize water-in-oil (w/o) emulsions and higher values indicating a preference for o/w emulsions. When the HLB value is greater than 10, it indicates a more hydrophilic surfactant that stabilizes the dispersion of oil droplets in water. This characteristic is essential for creating stable o/w emulsions, as the surfactant molecules preferentially orient themselves with their hydrophilic heads in the aqueous phase and their hydrophobic tails interacting with the oil phase. This arrangement facilitates the formation and stabilization of o/w emulsions, making the correct choice relevant to this context. Other options, such as w/o emulsions or coarse emulsions, involve different types of surfactants or mixtures that would not utilize nonionic surfactants with high HLB values effectively.

**6. What type of epithelium lines the alveoli of the lungs?**

**A. Cuboidal epithelium**

**B. Squamous epithelium**

**C. Columnar epithelium**

**D. Transitional epithelium**

The alveoli of the lungs are lined with squamous epithelium, specifically a type known as simple squamous epithelium. This type of epithelium is composed of a single layer of flat cells, which allows for efficient gas exchange between the air in the alveoli and the blood in the surrounding capillaries. The thinness of the squamous epithelium minimizes the distance that oxygen and carbon dioxide must diffuse, facilitating the rapid transfer of these gases during respiration. Additionally, the vast surface area provided by the numerous alveoli enhances the lungs' capacity for gas exchange, making this epithelium particularly suited for their function. Other types of epithelium, such as cuboidal and columnar, are not ideal for the specific needs of the alveoli because they would introduce additional thickness and potentially hinder the efficient passage of gases. Transitional epithelium, primarily found in the urinary bladder, is specialized for areas that stretch and contract, which is not relevant to the structure and function of the alveoli. Thus, the presence of simple squamous epithelium in the lungs is essential for their role in respiratory physiology.

**7. What is the acceptable droplet diameter range for an emulsion to be classified as coarse dispersion?**

- A. 1 nm to 0.1  $\mu\text{m}$
- B. 0.1  $\mu\text{m}$  to 10  $\mu\text{m}$**
- C. 10  $\mu\text{m}$  to 100  $\mu\text{m}$
- D. 100  $\mu\text{m}$  and above

In the context of emulsions and their classification, a coarse dispersion typically refers to a system where the dispersed droplets are larger in size. The acceptable droplet diameter range for classifying an emulsion as a coarse dispersion falls between 0.1 micrometers ( $\mu\text{m}$ ) and 10 micrometers ( $\mu\text{m}$ ). This range is significant because emulsions within this size bracket exhibit distinct physical properties and behaviors, often leading to their separation over time due to gravitational forces. Emulsions with droplet sizes smaller than 0.1  $\mu\text{m}$  are typically classified as fine or micro-emulsions, and sizes below 1 nanometer are classified as molecular dispersions, which involve solubilized substances rather than true emulsions. On the upper end, droplets larger than 10  $\mu\text{m}$  would not typically be classified as emulsions, as they can lead to more pronounced sedimentation and separation, thus altering the intended application of the emulsion. This classification is crucial in various pharmaceutical and cosmetic formulations, as it influences the stability, delivery, and overall effectiveness of the product. Therefore, the range of 0.1  $\mu\text{m}$  to 10  $\mu\text{m}$  accurately reflects the typical characteristics and behaviors of coarse dispersions in emulsions.

**8. Which form of DUR is performed after therapy has been completed?**

- A. Prospective DUR
- B. Concurrent DUR
- C. Retrospective DUR**
- D. Preventive DUR

Retrospective Drug Utilization Review (DUR) is a process conducted after a patient's therapy has been completed. This form of DUR involves reviewing a patient's medication therapy and health outcomes after treatment to evaluate the appropriateness, safety, and effectiveness of the medications that were prescribed. The goal is to identify any potential issues such as adverse drug reactions or interactions that may have occurred during the therapy. In contrast, prospective DUR is conducted before medication therapy begins, helping to identify potential problems ahead of time. Concurrent DUR occurs while the therapy is ongoing, allowing for real-time monitoring and adjustments based on the patient's current treatment. Preventive DUR is not a standard term broadly recognized within the context of DUR categories, and it does not specifically describe a recognized phase in the medication utilization review process. Understanding the timing and purpose of these different types of DUR is crucial for pharmacists in ensuring optimal patient care and medication management.

**9. Which agency is involved in coordinating and funding substance abuse and mental health programs?**

- A. FDA
- B. CMS
- C. SAMHSA**
- D. NIH

The Substance Abuse and Mental Health Services Administration (SAMHSA) is the agency responsible for coordinating and funding substance abuse and mental health programs in the United States. SAMHSA's mission is to reduce the impact of substance abuse and mental illness on communities, families, and individuals by promoting effective access to treatment and prevention strategies. The agency provides financial assistance to programs that develop or improve services for individuals experiencing substance abuse disorders, as well as mental health conditions. SAMHSA also undertakes efforts to raise awareness about mental health and substance use issues, emphasizing the importance of integrated care approaches and supporting public health initiatives. By working with state, local, and tribal governments, SAMHSA plays a crucial role in implementing programs and policies that help address these challenges on a national level. In contrast, the other options focus on different aspects of healthcare. The Food and Drug Administration (FDA) primarily regulates medications and food products, the Centers for Medicare & Medicaid Services (CMS) administers national health programs, and the National Institutes of Health (NIH) conducts research for medical advancements. Each of these agencies plays an important role in the health system, but SAMHSA is specifically dedicated to the coordination and funding of substance abuse and mental health programs.

**10. What defines low-risk level preparations according to USP 797?**

- A. Using nonsterile ingredients
- B. Multiple sterile product combinations
- C. Aseptic manipulations in ISO Class 5 conditions**
- D. Long duration manipulations

Low-risk level preparations, as defined by USP 797, must be compounded using sterile ingredients and require aseptic manipulations to ensure sterility throughout the process. The environment for these manipulations must be controlled, specifically within an ISO Class 5 area or better, to minimize contamination risks. Using aseptic techniques in an ISO Class 5 environment ensures that the preparation process is performed under conditions that provide a high level of protection against microbial contamination. This is essential for maintaining the quality and safety of the compounded sterile preparations. Thus, focusing on aseptic manipulations in an appropriate environment is critical for defining low-risk compounding. While other options might present relevant concepts around preparation, they do not meet the strict criteria laid out by USP 797 for low-risk level preparations. For example, nonsterile ingredients do not align with the requirements for sterile compounding, while multiple sterile product combinations or prolonged manipulations may indicate a higher level of risk. Hence, the emphasis on proper aseptic techniques within a controlled environment is the definitive criterion for low-risk level preparations.